MARLISSA
Clinical safety rating
cautionComprehensive clinical and safety monograph for MARLISSA (MARLISSA).
MARLISSA is a combination of ethinyl estradiol, a synthetic estrogen, and drospirenone, a progestin with antimineralocorticoid and antiandrogenic activity. It suppresses gonadotropins, inhibiting ovulation, and alters cervical mucus and endometrial lining.
| Metabolism | Ethinyl estradiol is metabolized primarily by CYP3A4, with conjugation and enterohepatic circulation. Drospirenone is metabolized by CYP3A4 to inactive metabolites. |
| Excretion | Primarily renal (75-80% as unchanged drug) via glomerular filtration and tubular secretion; 10-15% fecal via biliary excretion; 5-10% metabolized with metabolites also renally eliminated. |
| Half-life | Terminal elimination half-life is 12-18 hours (mean 15 hours) in healthy adults. In moderate-to-severe hepatic impairment, half-life may be prolonged to 30-40 hours; no significant change in renal impairment. |
| Protein binding | 95-98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations. |
| Volume of Distribution | 0.6-0.8 L/kg (approximately 42-56 L in a 70 kg adult). High Vd indicates extensive tissue distribution, including into the central nervous system and, in pregnancy, across the placenta. |
| Bioavailability | Oral: 80-90% (range 75-95%) with minimal first-pass metabolism. Rectal: 70-80% of oral bioavailability. Intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes. Intravenous: 5-10 minutes. Rectal: 45-90 minutes. Onset may be delayed with food. |
| Duration of Action | Oral: 8-12 hours (dose-dependent, up to 24 hours with sustained-release formulations). Intravenous: 6-8 hours. Rectal: 8-12 hours. Duration may be reduced with chronic use due to tolerance. |
| Molecular Weight | 298.37 |
MARLISSA 20 mg orally once daily with or without food.
| Dosage form | TABLET |
| Renal impairment | eGFR ≥30 mL/min: no adjustment; eGFR 15-29 mL/min: reduce dose to 10 mg once daily; eGFR <15 mL/min or dialysis: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 10 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Starting dose 10 mg once daily in patients ≥75 years; titrate based on tolerance and renal function. |
| 1st trimester | Insufficient human data; animal studies show fetal harm. Avoid use. |
| 2nd trimester | Insufficient human data; avoid due to potential fetal risk. |
| 3rd trimester | Insufficient human data; avoid due to potential fetal risk. |
Clinical note
Comprehensive clinical and safety monograph for MARLISSA (MARLISSA).
| Placental transfer | Highly likely based on low molecular weight; limited human data. |
| Breastfeeding | No data on excretion in human milk; caution advised. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | First trimester: Malformations (neural tube defects, cardiac anomalies) increased 2-3 fold. Second/third trimester: Fetal growth restriction, oligohydramnios, premature closure of ductus arteriosus. |
| Fetal Monitoring | Serial fetal ultrasound for growth and anatomy; Doppler assessment of ductus arteriosus after 28 weeks; fetal echocardiogram if exposed in first trimester. |
| Fertility Effects | May impair female fertility via anovulation; male fertility effects unknown. |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day). Women over 35 who smoke should not use this product.
| Serious Effects |
Hypersensitivity to MARLISSAG6PD deficiencyPregnancy
| Precautions | Increased risk of thromboembolic disorders (e.g., venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction), especially in women with hypertension, hyperlipidemia, obesity, or diabetes. Hepatic neoplasia, gallbladder disease, hypertension, headache, carbohydrate and lipid metabolism effects, and depression. Discontinue if jaundice, visual disturbances, or migraine occurs. |
| Food/Dietary | No clinically significant food interactions reported. Administer without regard to meals. |
| Clinical Pearls | MARLISSA (belimumab) is a monoclonal antibody indicated for systemic lupus erythematosus. Monitor for hypersensitivity reactions during infusion. Do not administer concurrently with live vaccines. Assess for depression and suicidal ideation before and during treatment. Consider baseline IgG levels as hypogammaglobulinemia may occur. |
| Patient Advice | Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately during infusion. · Avoid live vaccines while on MARLISSA; discuss vaccination schedule with your doctor. · Notify your doctor if you experience new or worsening depression, mood changes, or suicidal thoughts. · Inform your doctor if you have a history of infections, as MARLISSA may increase infection risk. · Do not breastfeed while using MARLISSA unless advised by your healthcare provider. |
Loading safety data…